Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction

Andrew E. Epstein, William T. Abraham, Nicole R. Bianco, Karl B. Kern, Michael Mirro, Sunil V. Rao, Edward K. Rhee, Scott D. Solomon, Steven J. Szymkiewicz

Research output: Contribution to journalArticlepeer-review

143 Scopus citations


Objectives The aim of this study was to describe usage of the wearable cardioverter-defibrillator (WCD) during mandated waiting periods following myocardial infarction (MI) for patients perceived to be at high risk for sudden cardiac arrest (SCA). Background Current device guidelines and insurance coverage require waiting periods of either 40 days or 3 months before implanting a cardioverter-defibrillator post-myocardial infarction (MI), depending on whether or not acute revascularization was undertaken. Methods We assessed characteristics of and outcomes for patients who had a WCD prescribed in the first 3 months post-MI. The WCD medical order registry was searched for patients who were coded as having had a "recent MI with ejection fraction ≤35%" or given an International Classification of Diseases, Ninth Revision 410.xx diagnostic code (acute MI), and then matched to device-recorded data. Results Between September 2005 and July 2011, 8,453 unique patients (age 62.7 ± 12.7 years, 73% male) matched study criteria. A total of 133 patients (1.6%) received 309 appropriate shocks. Of these patients, 91% were resuscitated from a ventricular arrhythmia. For shocked patients, the left ventricular ejection fraction (LVEF) was ≤30% in 106, 30% to 35% in 17, >36% in 8, and not reported in 2 patients. Of the 38% of patients not revascularized, 84% had a LVEF ≤30%; of the 62% of patients revascularized, 77% had a LVEF ≤30%. The median time from the index MI to WCD therapy was 16 days. Of the treated patients, 75% received treatment in the first month, and 96% within the first 3 months of use. Shock success resulting in survival was 84% in nonrevascularized and 95% in revascularized patients. Conclusions During the 40-day and 3-month waiting periods in patients post-MI, the WCD successfully treated SCA in 1.4%, and the risk was highest in the first month of WCD use. The WCD may benefit individual patients selected for high risk of SCA early post-MI.

Original languageEnglish (US)
Pages (from-to)2000-2007
Number of pages8
JournalJournal of the American College of Cardiology
Issue number21
StatePublished - Nov 19 2013


  • defibrillation
  • implantable cardioverter-defibrillator
  • resuscitation
  • sudden cardiac arrest
  • wearable cardioverter-defibrillator

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction'. Together they form a unique fingerprint.

Cite this